Novo Nordisk A/S $NVO Position Increased by Wealthspire Advisors LLC

Wealthspire Advisors LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 4.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,092 shares of the company’s stock after purchasing an additional 1,208 shares during the period. Wealthspire Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,870,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NVO. Empowered Funds LLC boosted its holdings in Novo Nordisk A/S by 62.9% in the second quarter. Empowered Funds LLC now owns 74,083 shares of the company’s stock worth $5,113,000 after purchasing an additional 28,613 shares in the last quarter. Pinnacle Wealth Planning Services Inc. increased its holdings in shares of Novo Nordisk A/S by 22.7% during the 2nd quarter. Pinnacle Wealth Planning Services Inc. now owns 18,790 shares of the company’s stock worth $1,297,000 after purchasing an additional 3,477 shares during the period. Frank Rimerman Advisors LLC lifted its position in shares of Novo Nordisk A/S by 19.5% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 25,615 shares of the company’s stock worth $1,768,000 after acquiring an additional 4,173 shares during the period. Capital Square LLC bought a new position in shares of Novo Nordisk A/S during the 2nd quarter worth about $605,000. Finally, Mosaic Family Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 17.2% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,748 shares of the company’s stock valued at $259,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on NVO shares. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. TD Cowen cut their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $49.07 on Thursday. The company has a 50 day moving average of $54.20 and a 200-day moving average of $60.61. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $112.52. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $219.08 billion, a P/E ratio of 13.48, a P/E/G ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.74 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.